{"schema_version":"secwatch.filing_event.v1","accession":"0001703057-26-000037","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2026-07-06T18:53:55+00:00","discovered_at":"2026-07-06T18:55:00.770847+00:00","generated_at":"2026-07-06T18:55:06.127697+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"AbCellera appoints Dr. Lynn Seely to Board of Directors as independent Class III director","bullets":["Dr. Lynn Seely appointed as Class III director effective June 30, 2026, serving until 2029 annual meeting.","She is independent under Nasdaq rules and will receive standard non-employee director compensation.","Dr. Seely is President and CEO of Lyell Immunopharma, former CEO of Myovant Sciences, and former CMO of Medivation.","Her experience includes endocrinology, oncology, and women's health, relevant to AbCellera's antibody-based medicine development."],"urls":{"canonical":"https://secwatch.observer/filing/0001703057-26-000037","json":"https://secwatch.observer/filing/0001703057-26-000037.json","markdown":"https://secwatch.observer/filing/0001703057-26-000037.md","text":"https://secwatch.observer/filing/0001703057-26-000037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/0001703057-26-000037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/abcl-20260630.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-06T18:55:06.127697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf2444eba4","claim":"Lynn Seely was appointed as Class III Director at AbCellera Biologics Inc..","evidence_excerpt":"On June 30, 2026, the Board of Directors (the \"Board\") of AbCellera Biologics Inc. (the \"Company\") appointed Lynn Seely, M.D as a new Class III director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703057/000170305726000037/0001703057-26-000037-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}